Wang W - Search Results

1

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer.

Liu Q, Chu Y, Shao J, Qian H, Yang J, Sha H, Cen L, Tian M, Xu Q, Chen F, Yang Y, Wang W, Wang K, Yu L, Wei J, Liu B. Liu Q, et al. Among authors: wang w, wang k. Adv Sci (Weinh). 2022 Nov 9;10(1):e2203298. doi: 10.1002/advs.202203298. Online ahead of print. Adv Sci (Weinh). 2022. PMID: 36351249 Free PMC article.

2

Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.

Liu F, Zhong F, Wu H, Che K, Shi J, Wu N, Fu Y, Wang Y, Hu J, Qian X, Fan X, Wang W, Wei J. Liu F, et al. Among authors: wang w, wang y. Oncologist. 2023 Mar 17;28(3):e136-e144. doi: 10.1093/oncolo/oyac268. Oncologist. 2023. PMID: 36724040 Free PMC article.

3

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China.

Xu Y, Shi X, Wang W, Zhang L, Cheung S, Rudolph M, Brega N, Dong X, Qian L, Wang L, Yuan S, Tan DSW, Wang K. Xu Y, et al. Among authors: wang w, wang l, wang k. NPJ Precis Oncol. 2023 Aug 11;7(1):75. doi: 10.1038/s41698-023-00427-3. NPJ Precis Oncol. 2023. PMID: 37567953 Free PMC article.

4

Development and validation of a gene expression-based nomogram to predict the prognosis of patients with cholangiocarcinoma.

Wang W, Wu C, Xu L, Li P, Wang K, Li G, Zhao S, Li Y, Fan X, Wang W, Hu M, Wu J, Xu S. Wang W, et al. Among authors: wang k. J Cancer Res Clin Oncol. 2023 Sep;149(12):9577-9586. doi: 10.1007/s00432-023-04858-0. Epub 2023 May 24. J Cancer Res Clin Oncol. 2023. PMID: 37222808 Free PMC article.

5

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03.

Sheng X, Chen H, Hu B, Yao X, Liu Z, Yao X, Guo H, Hu Y, Ji Z, Luo H, Shi B, Liu J, Wu J, Zhou F, He Z, Fan J, Wang W, Feng H, Yao S, Keegan P, Huang Y, Guo J. Sheng X, et al. Among authors: wang w. Clin Cancer Res. 2022 Feb 1;28(3):489-497. doi: 10.1158/1078-0432.CCR-21-2210. Epub 2021 Nov 5. Clin Cancer Res. 2022. PMID: 34740921 Clinical Trial.

6

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.

Zhou J, Sun Y, Zhang W, Yuan J, Peng Z, Wang W, Gong J, Yang L, Cao Y, Zhao H, Chen C, Wang W, Shen L, Zhou A. Zhou J, et al. Among authors: wang w. Hepatology. 2023 Jan 1;77(1):65-76. doi: 10.1002/hep.32548. Epub 2022 Aug 18. Hepatology. 2023. PMID: 35491432 Free PMC article. Clinical Trial.

7

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.

Tang B, Chi Z, Chen Y, Liu X, Wu D, Chen J, Song X, Wang W, Dong L, Song H, Wu H, Feng H, Yao S, Qin S, Zhang X, Guo J. Tang B, et al. Among authors: wang w. Clin Cancer Res. 2020 Aug 15;26(16):4250-4259. doi: 10.1158/1078-0432.CCR-19-3922. Epub 2020 Apr 22. Clin Cancer Res. 2020. PMID: 32321714

8

Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial.

Lu M, Zhang P, Zhang Y, Li Z, Gong J, Li J, Li J, Li Y, Zhang X, Lu Z, Wang X, Zhou J, Peng Z, Wang W, Feng H, Wu H, Yao S, Shen L. Lu M, et al. Among authors: wang x, wang w. Clin Cancer Res. 2020 May 15;26(10):2337-2345. doi: 10.1158/1078-0432.CCR-19-4000. Epub 2020 Feb 21. Clin Cancer Res. 2020. PMID: 32086343 Clinical Trial.

9

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).

Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, Yuan XL, Huang HX, Chen Y, Dai GH, Shi JH, Shen L, Yang SJ, Shu YQ, Liu YP, Wang W, Wu H, Feng H, Yao S, Xu RH. Wang FH, et al. Among authors: wang w. J Clin Oncol. 2021 Mar 1;39(7):704-712. doi: 10.1200/JCO.20.02712. Epub 2021 Jan 25. J Clin Oncol. 2021. PMID: 33492986 Free PMC article. Clinical Trial.

10

Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay.

Qi Z, Li Y, Wang Z, Tan X, Zhou Y, Li Z, Zhao W, Zheng X, Yao J, Li F, Wang W, Wang Z, Pang F, Wang G, Gu W. Qi Z, et al. Among authors: wang w, wang g, wang z. Cancer Med. 2023 Aug;12(16):16687-16696. doi: 10.1002/cam4.6286. Epub 2023 Aug 21. Cancer Med. 2023. PMID: 37602656 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

82,578 results

Search Page